DCx Biotherapeutics Corporation
Targeting cancer at its cellular roots to revolutionize patient outcomes.
Our Vision
Who We Are
We strive to address the root drivers of cancer by uncovering key cellular interdependencies that result from genetic lesions.
We can realize the full potential of antibody drug conjugates by targeting lesion-defined and synergistic targets to improve selectivity, potency, and tolerability with the ultimate aim to maximize clinical responses and durability.
Our Approach
MuSic™ Platform
Integrated CRISPR, bioinformatics, and machine learning platforms to identify lesion-specific intracellular and cell-surface targets that can be synergistically targeted to improve therapeutic responses and outcomes.
Healthy Cell
Expression of wildtype proteins obeys cell lineage and physiological external cues that maintain tissue homeostasis.
Tumor Cell
Genetic lesions (or mutations) drive the up-regulation of multiple pathways that promote tumor survival and tumorigenesis.
Multiple synergistic druggable targets addressable with multi-modal, multi-specific therapeutics.
- Genetic lesions causes aberrant expression / upregulation of intracellular and cell-surface proteins
- Mutated intracellular proteins can promote tumor survival and/or tumorigenesis and can be targeted with potent small molecules
- Aberrantly expressed cell-surface proteins can cooperate with other natural proteins to enhance tumorigenesis and/or tumor survival and can be precisely targeted with biologics
Multi-Modal Antibody Drug Conjugates (MM-ADCs)
Initial focus on developing lesion-specific MM-ADCs comprising of these synergistic components:
1. Functional Antibodies
- Modulate target-mediated activities
- Internalize to deliver payloads intracellularly
- Mediates effector functions through the Fc
- Potentiates the effect of biologically selective payloads
2. Biologically Selective Payloads
- Selective to targets driven by genetic lesions
- Induce immunogenic cell death
- Potentiates the function of lesion-specific antibodies
How Multi-Modal ADCs Work to Inhibit Tumor Survival and Tumorigenesis
Advantages to Deploying Multiple Lesion-Specific Synergistic Mechanisms of Action in Treating Cancers:
Enhanced & Prolonged Efficacy
- Eliminating tumor escape mechanisms
- Enhancing immune engagement
Improved Tolerability & Minimizing Side Effects
- Localizing to tumors with dual logic-gate between payloads and antibodies
- Avoiding broadly chemotoxic agents
- Advancing to earlier lines of therapies
Improved Selection of Patients
- Patients most likely to respond to harbor the cancer lesion of focus
- Focus on well known and commonly tested genetics lesions with high unmet needs
Get in Touch
Contact Us
If you are interested to learn more about our mission at DCx Bio and to explore collaboration opportunities, please reach out with your contact details!
"*" indicates required fields
Latest News
DCx Accelerates Multi-Modal ADC Development
Newly launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure from Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates Combines cancer…
